Identification of the secreted macromolecular immunogens of Staphylococcus aureus by analysis of serum

Royan, S

doi:10.1016/s0928-8244(00)00223-6

Cited by 5 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some investigators used whole cells or extracts [16,20], however, others pointed out the complexity caused by IgG-binding protein A and the potential advantages of using recombinant antigens [16,17,20]. Some investigators reported that patients with infection generally had higher antibody levels against purified proteins or recombinant antigens than healthy controls, and observed degrees of overlap between patients with infection and control subjects [8,13,33,44] similar to those reported here. None pursued the IgG responses for use in diagnostic applications.…”

Section: Sensitivity (%)supporting

confidence: 65%

“…Additionally, while serum diagnostics are available for several microbial pathogens, no host immunity test is available for S aureus infections. To this end, several groups have described the anti-S aureus humoral immune response in physiologic and pathological situations [12,13,33,39,41,42,44]. Gedbjerg et al [15] described an antiglucosaminidase antibody test to assess infection and prognosis in patients undergoing orthopaedic surgery who have a confirmed S aureus infection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis

Nishitani

Beck

Rosenberg

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Because immunity against Staphylococcus aureus has not been fully elucidated, there is no diagnostic test to gauge how robust a patient's host response is likely to be. Therefore, we aimed to develop a test for specific antibodies in serum with diagnostic and prognostic potential. Questions/Purposes We describe the development and validation of a multiplex immunoassay for characterizing a patient's immune response against 14 known S aureus antigens, which we then used to answer four questions: (1) Do certain antigens predominate in the immune response against S aureus? (2) Is there a predominant pattern of antigens recognized by patients and mice with infections? (3) Is the immunoglobulin G (IgG) response to any single antigen a useful predictor of ongoing S aureus infection? (4) Does measurement of the combined response against all 14 antigens provide a better predictor of ongoing infection? Methods A case-control study was performed. Sera were collected from 35 consecutive patients with S aureus culture-confirmed (methicillin-sensitive S aureus or methicillin-resistant S aureus) musculoskeletal infections The institution of one or more of the authors (EMS, SLK, JLD, CAB) has received, during the study period, funding from the National Institutes of Health, NIAMS (Bethesda, MD, USA) and (EMS, SLK, JLD) the AOTrauma Clinical Priority Program (Davos, Switzerland). One of the authors certifies that he (JLD) or she or a member of his or her immediate family, has received or may receive payments or benefits, during the study period, an amount of USD 10,000 to 100,000 from Telephus Medical LLC (San Diego, CA, USA) and an amount of less than USD 10,000 from Calorics Pharmaceuticals (Waltham, MA, USA). One of the authors certifies that he (EMS) or she or a member of his or her immediate family, has received or may receive payments or benefits, during the study period, an amount of USD 10,000 to 100,000 from Telephus Medical LLC (San Diego, CA, USA). One of the authors certifies that he (SLK) or she or a member of his or her immediate family, has received or may receive payments or benefits, during the study period, an amount of less than USD 10,000 from Surgical Excellence Healthcare Quality Consulting, and an amount of USD 10,000 to 100,000 from Sage Publications (Thousand Oaks, CA, USA) One of the authors certifies that he (CAB) or she or a member of his or her immediate family, has received or may receive payments or benefits, during the study period, an amount of USD 10,000 to 100,000 from the FDA (Silver Spring, MD, USA), and an amount of USD 10,000 to 100,000 from Boston Scientific (Marlborough, MA, USA), an amount of USD 10,000 to 100,000 from Lundbeck Inc (Deerfield, IL, USA), an amount of USD 10,000 to 100,000 from Patient-Centered Outcomes Research Institute (PCORI, Washington, DC, USA), and an amount of less than USD 10,000 from Auspex Pharmaceuticals (La Jolla, CA, USA). All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research 1 editors and board mem...

show abstract

Section: Sensitivity (%)supporting

confidence: 65%

Section: Introductionmentioning

confidence: 99%

A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis

Nishitani

Beck

Rosenberg

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…Our ELISA analyses with selected staphylococcal proteins suggested that the antistaphylococcal antibody repertoires from healthy and diseased individuals overlap. Similarly, a proteomic analysis showed that sera from healthy donors and infected patients recognize a similar pattern of antigens from S. aureus (47). These data prompted us to identify staphylococcal antigens by the use of antibodies from high-titer sera from healthy people in a comprehensive genomic screening method (14).…”

Section: Figmentioning

confidence: 99%

Comparison of Antibody Repertoires against Staphylococcus aureus in Healthy Individuals and in Acutely Infected Patients

Dryla

Prustomersky

Gelbmann

et al. 2005

Clin Vaccine Immunol

173

172

View full text Add to dashboard Cite

The management of staphylococcal diseases is increasingly difficult with present medical approaches. Preventive and therapeutic vaccination is considered to be a promising alternative; however, little is known about immune correlates of protection and disease susceptibility. To better understand the immune recognition of Staphylococcus aureus by the human host, we studied the antistaphylococcal humoral responses in healthy people in comparison to those of patients with invasive diseases. In a series of enzyme-linked immunosorbent assay analyses performed using 19 recombinant staphylococcal cell surface and secreted proteins, we measured a wide range of antibody levels, finding a pronounced heterogeneity among individuals in both donor groups. The analysis revealed marked differences in the antibody repertoires of healthy individuals with or without S. aureus carriage, as well as in those of patients in the acute phase of infection. Most importantly, we identified antigenic proteins for which specific antibodies were missing or underrepresented in infected patients. In contrast to the well-described transient nature of disease-induced antistaphylococcal immune response, it was demonstrated that high-titer antistaphylococcal antibodies are stable for years in healthy individuals. In addition, we provide evidence obtained on the basis of opsonophagocytic and neutralizing activity in vitro assays that circulating antistaphylococcal serum antibodies in healthy donors are functional. In light of these data we suggest that proper serological analysis comparing the preexisting antibody repertoires of hospitalized patients with different outcomes for nosocomial staphylococcal infections could be extremely useful for the evaluation of candidate vaccine antigens in addition to protection data generated with animal models.Staphylococcus aureus is one of the most common bacterial causes of infections in both hospitals and communities and imposes a medical problem of increasing severity (5, 12). Coagulase-positive S. aureus is the most pathogenic staphylococcal species and an opportunistic pathogen that can cause illnesses ranging from minor infections to life-threatening diseases. The high incidence of staphylococcal infections is related to an increase in the use of catheters and prosthetic devices and in the number of immunity-compromised patients. Importantly, the emergence and the disease-causing capacity of staphylococci are strongly related to the widespread use of antibiotics combined with the enormous potential of this bacterium to develop multidrug resistance (31, 45). Moreover, the most serious staphylococcal infections are still associated with high mortality, despite the availability of effective antibiotics. As a consequence, new medical treatment regimens are needed in the management of staphylococcal diseases. Immunological approaches such as antistaphylococcal vaccination certainly have the potential for preventive and therapeutic treatment. However, despite the high prevalence of and medical need to prevent ...

show abstract

“…The anti-S. aureus antibody patterns from healthy individuals and patients overlap strongly (Dryla et al, 2005;Royan et al, 2000;Vytvytska et al, 2002). There are two non-exclusive explanations for this: (1) The antibodies observed in healthy individuals are generated in response to minor infection, and (2) the protein expression patterns of S. aureus in colonization and invasion are similar.…”

Section: Infectionmentioning

confidence: 99%

Towards the immune proteome of Staphylococcus aureus – The anti-S. aureus antibody response

Holtfreter

Kolata

Bröker

2010

International Journal of Medical Microbiology

View full text Add to dashboard Cite

Identification of the secreted macromolecular immunogens of Staphylococcus aureus by analysis of serum

Cited by 5 publications

References 16 publications

A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis

A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis

Comparison of Antibody Repertoires against Staphylococcus aureus in Healthy Individuals and in Acutely Infected Patients

Towards the immune proteome of Staphylococcus aureus – The anti-S. aureus antibody response

Contact Info

Product

Resources

About